Almost everything written about semen retention argues about the population. Does it raise testosterone, does it sharpen focus, is the flatline real. Those arguments are worth having and they are had elsewhere on this site. This page is about a different question, and it is the only one you can actually settle: what happens to you.
Getting at that is not a matter of reading harder. It is a matter of design. What follows is why group findings often fail to describe individuals, what a single-person experiment actually requires, the specific ways people running one fool themselves, and the one large trial that tested whether any of this makes people better off. That last result undercuts the enterprise, and leaving it out would be the exact error this site is written against.
The average is not you
There are two arguments here, one mathematical and one empirical, and they say slightly different things.
Molenaar's is the mathematical one. Under the classical ergodic theorems, a structure found in variation between people transfers to variation within a person only if strict conditions hold: essentially stationarity over time and homogeneity across people. Real psychological processes rarely satisfy either. So group-to-individual transfer is something that has to be demonstrated, not assumed.
Fisher, Medaglia and Jeronimus put numbers on it. Across six repeated-measures samples of 87 to 94 participants each, group and individual estimates of central tendency broadly agreed, but the variance around the expected value was two to four times larger within individuals than within groups. The practical reading is precise and useful: the group mean is often a fair guess at where a person sits on average, and a poor guide to how much any individual swings. Swing is the thing a practitioner cares about.
The studies are all averages, so they can't tell me what this will do to me.
The methodological half is supported and the sweeping half is not. Molenaar (2004) shows group-to-individual transfer requires assumptions that usually fail; Fisher et al. (2018), six samples of 87 to 94 people, found within-person variance two to four times larger than within-group variance. What that licenses is narrow: the transfer must be shown rather than assumed, and an average is a weak description of an individual's variability. It does not license the conclusion that group research is useless or that science can say nothing about you. A later exchange in the same journal also noted that ergodicity is sufficient but not strictly necessary for group-to-individual generalisability.
What an n-of-1 trial actually is
The single-patient trial is not a euphemism for anecdote. Guyatt and colleagues introduced the modern clinical form in 1986: one patient runs a series of randomised, blinded pairs of periods, one active and one comparator per pair, continuing until the answer is clear. Their group reported 57 completed trials from three years of routine clinical use, although the measure of success there was physician confidence in the resulting management plan, which is an investigator judgement rather than a blinded outcome. Duan, Kravitz and Schmid set out the decision framework, CENT 2015 extended the CONSORT reporting standard to n-of-1 trials with guidance on 14 of the 25 items, and AHRQ published a full methods guide.
The 2011 Oxford Centre for Evidence-Based Medicine levels place n-of-1 randomised trials conducted in the very patient asking the question at Level 1 for treatment benefit, alongside systematic reviews of randomised trials. That line is widely mangled online into the claim that n-of-1 beats randomised controlled trials, full stop.
An n-of-1 trial is higher-quality evidence than a randomised controlled trial.
True only in the reading OCEBM actually intends, and false in the reading people quote. A large trial estimates an average effect and answers what should be tried first in someone like you. An n-of-1 trial answers whether it works in you, and generalises to nobody else. OCEBM's own explanation flags the ambiguity. Level 1 status also requires an actual trial with randomised or alternated periods, not a diary of one uninterrupted stretch.
The one trial of the method itself
One large randomised trial has tested whether supporting people to run rigorous self-experiments actually improves their outcomes. PREEMPT randomised 215 primary care patients with chronic musculoskeletal pain, 108 to a smartphone-supported single-patient multi-crossover trial comparing two self-selected pain regimens, 107 to usual care.
The intervention worked as a piece of engineering. Ninety-five of 108 intervention patients, 88 percent, completed their trial, and user experience was satisfactory. The primary outcome, PROMIS pain-related interference at six months, showed no significant difference between groups: 1.36 points, P equal to 0.09. Secondary outcomes were also null, with one exception, medication-related shared decision-making, which favoured the intervention by 11.9 points, P equal to 0.01.
A trial designed to detect the benefit did not detect it.
P equal to 0.09 sits close enough to convention that it invites being described as a near miss. It should not be. The honest summary is no significant improvement, not trending towards benefit. Structured self-experimentation is feasible, is acceptable to the people doing it, and improves the quality of the decision conversation. Its effect on how people feel months later is unproven. Anyone selling self-experimentation as a route to better outcomes, including anyone selling you an app, is going beyond the evidence.
Running a proper experiment on yourself will make you better off.
PREEMPT (Kravitz et al. 2018), 215 patients, found no significant benefit on its primary outcome at six months despite 88 percent trial completion. This is the only large randomised test of the idea, it was conducted in chronic pain rather than in this practice, and it came back null. One trial in the wrong population cannot show the idea is false, but nothing currently shows it is true. What the method can offer is a better answer to your question, not a better outcome.
Why "I felt completely different" is not a result
Senn's argument is the sharpest correction available to anyone who has felt transformed on day 21. A difference observed once between a treated and an untreated state confounds four things: true individual response, within-person random variation, measurement error, and time effects. Separating the first from the other three requires repeated within-person exposure to both conditions. A single comparison cannot do it, however large the apparent change. Senn's related point is that the responder versus non-responder dichotomy is usually an artefact, because the variance components needed to demonstrate real individual response are almost never estimated.
Two more mechanisms manufacture the same impression. Regression to the mean means unusually extreme measurements tend to be followed by measurements closer to a person's average, and the effect grows with measurement error and with selecting your comparison point on the basis of a bad baseline value. People start a practice during a bad week and then compare the following month against that week. That is the structure of the illusion.
And looking at your own chart does not rescue you. Matyas and Greenwood gave 37 postgraduate students trained in single-case design 27 charts generated from a first-order autoregressive model and asked them to judge whether an intervention effect was present. False alarm rates ranged from 16 percent to 84 percent, rising with positive autocorrelation and with variability in the series. Daily self-ratings of mood, energy and sleep are strongly autocorrelated: a good day tends to follow a good day. That is precisely the condition under which trained judges invent effects that are not there.
By day 21 I felt completely different, so it's clearly doing something for me.
You have learned that day 21 felt good. Senn (2018) sets out why one comparison cannot separate a true individual response from within-person variation, measurement error and time. Barnett et al. (2005) describe how regression to the mean produces apparent improvement when nothing works. Matyas and Greenwood (1990), 37 trained judges on 27 simulated charts, found false alarm rates of 16 to 84 percent under serial dependence. None of this says your experience was not real. It says the causal attribution is not established.
Expectancy, which you cannot remove
Blinding is the feature that makes clinical n-of-1 trials strong, and it is unavailable here. You always know which condition you are in. That matters because expectation alone moves self-reported outcomes. Kaptchuk and colleagues randomised 80 patients with irritable bowel syndrome to openly labelled placebo pills, described honestly as inert, or to no treatment with matched practitioner contact, and found significantly greater symptom improvement in the open-label arm over three weeks. A later systematic review found open-label placebos outperformed no treatment across the small set of trials available, with the authors noting the evidence base is small and the trials short.
The conclusion is not that self-reported benefit is fake. It is narrower and it is permanent: your experiment cannot distinguish the effect of abstaining from the effect of expecting abstaining to work. Design around it where you can, and stop claiming otherwise where you cannot.
What to measure, and how to rate it
Nothing has been validated for this practice. There is no published outcome set, no established time course for any claimed effect, and therefore no principled basis for choosing a block length or a washout period. The one number people reach for, the seven-day testosterone peak, comes from a 2003 paper in 28 volunteers reporting serum testosterone at 145.7 percent of baseline on day seven, which the journal's editor-in-chief retracted in 2021 for substantial overlap with a previously published Chinese-language article. It cannot be used as evidence for a peak, and it cannot be used as evidence against one either. Its only relevance here is that the figure most often used to pick a block length comes from a withdrawn paper.
The information environment is worth knowing too, because it is where most protocol advice comes from. Dubin and colleagues analysed 234 TikTok posts and 240 Instagram posts across six men's health topics. Semen retention was the largest topic by reach, with 1,216,074,000 TikTok impressions and 1,077,000 Instagram posts, it is reported as the topic lacking physician engagement, and it scored lowest of the six topics on the study's content accuracy rating, 1.5 out of 5. That is a description of posts, not of the practice.
There's a right thing to measure and a known number of days it takes to show up.
No outcome measure, effect size, time course or washout period has been established for this practice. Mood, energy, libido, sleep quality, focus and anxiety are all plausible candidates and none has been shown to be the sensitive one. Any block length you pick, including the ones recommended below, is reasoning rather than evidence. Anyone who tells you otherwise is guessing.
Rules that come from measurement, not from retention
With that stated plainly, here is what follows from general measurement methodology.
- One primary outcome, at most one secondary. Choe and colleagues analysed 52 Quantified Self talks and found that tracking too many things at once leads to tracking fatigue, and that failing to record context leaves people unable to explain what they observed.
- Identical wording, every single day. König and colleagues meta-analysed reactivity to digital in-the-moment measurement of health behaviour across 31 studies, pooling 7, and found small but meaningful effects, Cohen's d of 0.27 to 0.30. In the behaviours studied, and 81 percent of them were physical activity, measuring changes what is being measured. Holding the item constant at least keeps that effect constant across conditions.
- Same time of day, and rate the day on the day. Redelmeier and Kahneman recorded real-time pain in 154 colonoscopy patients and 133 lithotripsy patients and found retrospective global judgements tracked peak intensity and the final three minutes rather than duration. An end-of-month reflection is a reconstruction weighted by the best or worst moment. Reflective journalling is worth doing; it is not a measurement.
- A coarse scale, 0 to 10. Fine gradations imply a precision your self-report does not have.
- Rate the outcome, not the practice. "How was my energy today" is a measurement. "How is retention going" is a verdict you are asking yourself to defend. Grubbs and colleagues' meta-analysis found that moral incongruence about pornography use is associated with greater distress and higher perceived addiction independently of how much a person actually uses, which means any item phrased around failure is partly measuring your beliefs about the behaviour. Your own baseline is the only comparison that holds still.
- Treat the first week of any new measure as contaminated, and do not look at yesterday's number before entering today's.
Tracking is itself an intervention
One thing to say straight, because it cuts against tracking rather than for it. Harkin and colleagues meta-analysed 138 randomised studies with 19,951 participants and found that prompting people to monitor progress toward a goal reliably improved behavioural performance and goal attainment, with larger effects when progress was recorded. If you log daily, you are running two interventions at once, and your log cannot separate them.
Tracking is just neutral observation of what would have happened anyway.
Nothing supports the neutrality assumption. König et al. (2022), 31 studies from 11,723 records screened, found small but meaningful reactivity to digital in-the-moment measurement, d of 0.27 to 0.30, though 81 percent of that evidence concerns physical activity rather than mood or libido. Harkin et al. (2016), 138 studies and 19,951 participants, found monitoring progress toward a goal improves performance in its own right. Neither was conducted on these outcomes, so the size of the effect here is unknown. The response is to hold the procedure constant, not to abandon it.
Streak length is the worst available outcome measure
No trial has tested streak counters as an outcome measure, so what follows is a design argument, not an empirical result. It has three parts.
First, a streak is monotonic by construction. It only ever goes up, so it correlates with everything else that drifts with time: seasonal mood, a new job, the weather improving. Correlating streak length with mood is close to correlating mood with the calendar.
Second, a streak measures adherence to the condition. In trial terms that is exposure, not outcome.
A streak measures how well you complied, and calling compliance the result removes any possibility of finding nothing.
Third, the all-or-nothing framing carries a documented psychological cost in a different population. In the relapse prevention literature, the abstinence violation effect describes the guilt, shame and internal attribution that follow a lapse under an inflexible abstinence model, and endorsing those beliefs is associated with greater likelihood of relapse. That literature comes from substance use disorder treatment, the association is observational, and it does not transfer automatically to a voluntary self-improvement practice.
The alternative is simple. Record the condition each day as a state, abstaining or not, and record your outcomes separately. Then compare periods against each other. A lapse becomes a boundary in the data instead of a wiped score, and you keep the ability to find nothing.
The streak is the number that tells you how it's going.
The methodological objections are strong: a streak is confounded with time by construction, and it measures exposure rather than outcome, which makes a null result impossible. But no study has tested streak counters as outcome measures in this or any practice, so this is a design argument. The abstinence violation evidence (Larimer et al. 1999) is real but comes from substance use disorder populations and is observational. Treat it as a reason to design carefully, not as evidence about semen retention.
The protocol
The clinical literature is consistent about structure even where the numbers are not transferable. AHRQ's numeric recommendations are tied to drugs with known onset and offset; no equivalent parameters exist for a behavioural practice. So take the shape as sound and the durations as a guess.
- Baseline for two to four weeks. Change nothing about your practice. Measure daily. Use the baseline period average as your comparison, never the single day you decided to start, which is the day regression to the mean is waiting for.
- Fix your outcomes before day one. One primary, at most one secondary, wording written down.
- Write the prediction, and write the null. State how big a difference would have to be to matter to you, and what a result that would convince you the practice does nothing looks like. An experiment where no possible result would change your mind is not an experiment.
- Alternate blocks, roughly two to four weeks each. Not one long stretch. Aim for three or four blocks per condition so the pattern has a chance to repeat. Fix or randomise the order in advance.
- Accept that washout is unknown. A period should be long enough for an effect to appear and for the previous condition to fade. If it does not fade, carryover contaminates the comparison, and where washout is skipped the statistical literature now handles carryover and serial dependence in the analysis instead of ignoring them. Neither the onset nor the offset time for this practice has been measured, which is a real limit on the whole design.
- Record context alongside the outcome: sleep, training, alcohol, workload, anything else that changed. Choe and colleagues found failure to record context is what leaves self-trackers unable to explain what they saw.
- Change one thing at a time. This is the hardest rule and the one most often broken here, because people rarely start retention alone. The same week typically brings training, an earlier bedtime, less alcohol, deleted apps and a new social identity. Every one of those independently moves mood, sleep and energy. Add them one at a time or you will never know which term in the sum did the work.
- Plan for lapses in advance. In the closest thing to a controlled abstinence trial anyone has run, 176 undergraduates randomised to seven days of pornography abstinence or usual behaviour, 45.35 percent of the abstinence group lapsed at least once inside the week. That study was 64.2 percent female, in Malaysia, over seven days, with self-reported compliance, and it concerned pornography rather than retention. Read it only as a sense of how common a lapse is, and record yours as a state change rather than a failure.
- Decide the decision rule in advance, and commit to accepting a null. Every element of CENT 2015 exists because these are the choices that get quietly revised once results are in view.
What this can and cannot give you
Karkar and colleagues built a real self-experimentation app and field-tested it with 15 patients, and found people could run a reliable experiment while living with a persistent tension between scientific validity and the practical realities of everyday life. Roberts, whose twelve years of self-experimentation produced an unusually high rate of new hypotheses, framed the method as a way of generating ideas rather than confirming them, and his account was contested in the accompanying peer commentary. That is the accurate framing: self-experimentation produces candidate explanations efficiently and confirms them poorly.
It will not tell you what retention does in general. It will not remove expectancy. It has not been shown, on the PREEMPT evidence, to make people feel better. What it can do is tell one person what changed, when, and alongside what else, which is a smaller and more defensible claim than any population study in this area is currently in a position to make.
One last thing that is not methodology. Data is not a diagnosis. If your record shows persistent low mood, pain, or erectile difficulty, that is a reason to see a doctor, not a reason to add another block to the design.